MedPath

Clinical Trial News

Aspirin Shows No Benefit and Potential Harm in Colorectal Cancer Liver Metastases, Phase 3 Trial Finds

  • Daily adjuvant aspirin at 160 mg failed to improve disease-free survival in patients with colorectal cancer liver metastases compared to placebo in the randomized phase 3 ASAC trial.
  • The aspirin group showed a numerically higher risk for death that nearly reached statistical significance, with more adverse events and serious complications.
  • Results indicate the protective effects of aspirin observed in non-metastatic colorectal cancer do not translate to patients with liver metastases.
  • Researchers plan subgroup analyses for PIK3CA, PTEN, and KRAS mutations to identify potential patient populations who might benefit from aspirin therapy.

Aspirin in Colorectal Cancer Liver Metastases

NCT03326791Active, Not RecruitingPhase 2
Oslo University Hospital
Posted 12/15/2017

Adjuvant Low Dose Aspirin in Colorectal Cancer

NCT02647099Active, Not RecruitingPhase 3
Anna Martling
Posted 4/7/2016

T1D Exchange to Present 13 Real-World Data Studies at ADA 2025 Scientific Sessions

Real World Evidence
  • T1D Exchange will present 13 real-world data studies at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025.
  • The studies focus on advances in diabetes screening, mental health, health equity, and early intervention, with particular emphasis on continuous glucose monitoring adoption in type 2 diabetes patients using GLP-1 therapy.
  • The research draws from T1D Exchange's Quality Improvement Collaborative network of over 60 endocrinology clinics treating more than 150,000 patients and their Registry of over 20,000 type 1 diabetes participants.
  • The organization has contributed to more than 100 publications in leading medical journals since 2020, strengthening its leadership in diabetes research and care improvement.

OKYO Pharma's Eye Pain Drug Trial Ends Early, Analysts Raise Price Target 60% on Accelerated Timeline

  • OKYO Pharma's Phase 2 trial for urcosimod, a potential first-in-class treatment for neuropathic corneal pain, closed early after treating 17 patients instead of the planned 48, with top-line results now expected in Q3 2025.
  • Goldman Small Cap Research raised its price target for OKYO shares to $8 from $5, citing the early trial closure as potentially shortening the development pathway and accelerating time to market.
  • The drug targets neuropathic corneal pain, a debilitating condition with no FDA-approved therapies and an estimated market opportunity exceeding $6.4 billion.
  • OKYO's shares have nearly doubled since the start of 2025, driven by clinical progress and the FDA's Fast Track designation for urcosimod.

Northwest Biotherapeutics to Present Next-Generation Dendritic Cell Therapy Advances at Cancer Immunotherapy Conference

  • Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will present on "supercharged" dendritic cells with enhanced anti-tumor effects at the Frontiers in Cancer Immunotherapy Conference on June 16.
  • The company has completed a 331-patient Phase III trial of DCVax-L for glioblastoma and submitted a Marketing Authorization Application for commercial approval in the UK.
  • Northwest Biotherapeutics is developing DCVax-Direct for inoperable solid tumors, having completed a 40-patient Phase I trial with Phase II trials planned for this year.

Nusano Achieves 99.2% Purity in Gadolinium-160 Enrichment, Opens 190,000-Square-Foot Utah Facility

  • Nusano successfully enriched gadolinium-160 to 99.2% purity using proprietary in-house technology, significantly improving upon natural gadolinium's 21.86% concentration of the desired isotope.
  • The company unveiled its new 190,000-square-foot facility in West Valley City, Utah, featuring a 73-foot linear accelerator capable of producing over 25 different radioisotopes simultaneously.
  • The breakthrough establishes a domestic supply chain for stable isotopes critical to medical diagnostics and cancer therapies, reducing dependence on geopolitically-stressed nations.
  • Nusano's proprietary ion source technology produces alpha ions at volumes 100 times greater than any other facility globally, enabling high-volume, high-purity radioisotope manufacturing.

Bristol Myers Squibb Acquires Novel Prostate Cancer Radiopharmaceutical for $1.35 Billion

Targeted TherapyOncology
  • Bristol Myers Squibb agreed to pay $350 million upfront to Philochem for worldwide rights to OncoACP3, an experimental radiopharmaceutical targeting the ACP3 protein for prostate cancer diagnosis and treatment.
  • OncoACP3 targets ACP3, a biomarker highly expressed in prostate cancer that potentially exceeds PSMA expression levels, offering an alternative pathway to current PSMA-targeted therapies.
  • The deal includes up to $1 billion in additional milestone payments and royalties, positioning Bristol Myers to compete with Novartis in the rapidly expanding radiopharmaceutical market.
  • RayzeBio, Bristol Myers' radiopharmaceutical subsidiary acquired for $4.1 billion, will lead development of OncoACP3 through Phase 1 therapeutic testing.

uniQure Appoints Kylie O'Keefe as Chief Customer and Strategy Officer to Lead AMT-130 Commercialization for Huntington's Disease

Rare Disease
  • uniQure has appointed Kylie O'Keefe as Chief Customer and Strategy Officer to lead the global commercialization strategy for AMT-130, the company's investigational gene therapy for Huntington's disease.
  • O'Keefe brings extensive rare disease and gene therapy experience from her role as Chief Commercial Officer at PTC Therapeutics, where she led commercial launches across more than 50 countries.
  • The appointment positions uniQure for a potential U.S. commercial launch of AMT-130 in 2026, with the therapy having potential to become the first disease-modifying treatment for Huntington's disease.
  • AMT-130 is currently in Phase I/II clinical trials and has a clear pathway toward accelerated approval in the United States.

Biovica Sets Ambitious Revenue Targets Following Strategic Partnerships in Cancer Monitoring

  • Biovica International announces aggressive financial targets, projecting net sales growth from SEK 8.5 million in FY 2024/25 to SEK 150 million by FY 2026/27.
  • The company's DiviTum TKa blood-based biomarker assay for metastatic breast cancer monitoring has secured strategic partnerships with Tempus AI and over 15 pharmaceutical collaborations.
  • Revenue distribution is expected to be 65% from the U.S. market, 30% from pharma services, and 5% from European partners across 18 territories.
  • Biovica anticipates achieving cash-flow positive status during the third quarter of FY 2026/27 with current operating expenses of approximately 90 MSEK annually.

Sofinnova Partners and NVIDIA Launch AI Infrastructure Partnership to Accelerate European Life Sciences Innovation

AIDrug DiscoveryPrecision Medicine
  • Sofinnova Partners, a leading European life sciences venture capital firm, has partnered with NVIDIA to provide GPU credits and high-performance AI infrastructure to its portfolio companies through NVIDIA DGX Cloud Lepton.
  • Four promising European digital medicine startups—BioCorteX, Bioptimus, Cure51, and Latent Labs—are among the first cohort to gain access to NVIDIA's computational resources, enabling faster biological data processing and model development.
  • Cure51 demonstrated the partnership's potential by achieving up to 17x faster genomic processing and more than 2x cost savings using NVIDIA's GPU-accelerated genomics toolkit compared to traditional CPU methods.
  • The collaboration aims to position Europe at the forefront of AI-driven drug discovery by providing startups with computational power comparable to Silicon Valley tech giants in the $100B+ life sciences market.

Lifordi Presents Promising Preclinical Data for LFD-200 Glucocorticoid ADC at EULAR 2025

  • Lifordi Immunotherapeutics presented preclinical data for LFD-200, an antibody-drug conjugate delivering glucocorticoids directly to immune cells for autoimmune and inflammatory diseases.
  • Multiple studies in mice and non-human primates demonstrated that LFD-200 achieves targeted and sustained delivery of its glucocorticoid payload to immune cells.
  • The ADC showed efficacy without systemic toxicity by targeting myeloid and lymphoid cells using the VISTA cell surface membrane protein.
  • The company's platform technology can also deliver diverse payloads including small molecules, antisense oligonucleotides, and siRNA to immune cells.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.